Eutilex Receives FDA Approval for 'EU101' Phase 1/2 Clinical Trial Plan

[Asia Economy Reporter Kum Boryeong] Eutilex announced on the 15th that it has received approval from the U.S. Food and Drug Administration (FDA) for the clinical phase 1/2 trial plan of the immuno-oncology drug 'EU101'.

The title of the clinical trial is "An open-label, phase 1/2 clinical trial to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of EU101, an anti-CD137 (4-1BB) agonist monoclonal antibody, in patients with advanced solid tumors."

The target disease (indication) is solid tumors. The clinical trial sites are two hospitals in the United States.